PET and SPECT radiotracers have been developed to target specific markers on cancer cells that are upregulated relative to healthy tissue; notably PSMA, which is often overexpressed in prostate cancer 6,7, the somatostatin receptor 2 (SSTR2) which is commonly overexpressed on neuroendocrine tumors 8, and the fibroblast activation protein (FAP) 9, which is overexpressed in various tumor microenvironments. This evidence concerns the gene SSTR2 and prostate cancer.